Last updated: February 27, 2026
What is the drug associated with NDC 00703-7123?
NDC 00703-7123 corresponds to Tafasitamab (Monjuvi), a monoclonal antibody approved for relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It is marketed by MorphoSys under the brand name Monjuvi.
Market Overview
Indication and Patient Population
- Approved in August 2020 for adult patients with relapsed or refractory DLBCL not suitable for traditional chemo-immunotherapy.
- Estimated eligible patient population in the U.S. is approximately 10,000 annually, based on prevalence data.
Competitive Landscape
- Competes primarily with CAR-T therapies such as Axicabtagene Ciloleucel (Yescarta) and Tisagenlecleucel (Kymriah).
- Chemotherapy regimens serve as alternatives, but limited for refractory cases.
Drug Uptake and Adoption
- Early adoption by oncology centers, with a preference for non-chemotherapy options in refractory cases.
- Distribution channels include hospital outpatient clinics and specialty pharmacies.
Market Trends
- Growing preference for targeted antibody therapies over chemotherapy.
- Expansion into earlier lines of therapy pending ongoing clinical trials.
- Anticipated approval for combination regimens could increase market size.
Price and Reimbursement Data
Current Pricing
- List Price per treatment cycle: approximately $21,000.
- Typical course: 2-4 doses, with a total treatment cost around $84,000 to $168,000, depending on patient response and duration.
Factors Influencing Price
- High cost of manufacturing biologics.
- Reimbursement pressures from payers.
- Patient access programs and discounts.
Reimbursement Status
- Covered by Medicare, Medicaid, and commercial payers.
- Reimbursement rates vary, with average reimbursement approximately 75-85% of list price.
Market Projections
| Year |
Projected Patient Uptake |
Estimated Revenue |
Key Assumptions |
| 2023 |
1,200 patients |
$50 million |
12% of eligible population, 80% treatment initiation rate |
| 2024 |
1,500 patients |
$63 million |
Expansion into additional centers, increased clinician familiarity |
| 2025 |
2,000 patients |
$84 million |
Broadened indications, clinical trial success |
| 2026 |
2,500 patients |
$105 million |
Potential label expansion, increased third-line use |
Market Drivers
- Increasing approvals for combo use.
- Rising incidence of DLBCL.
- Enhanced clinical efficacy over traditional therapies.
Market Risks
- Competition from CART therapies with curative potential.
- Pricing pressures from payers.
- Regulatory delays or denials for label expansions.
Pricing Dynamics and Future Trends
- List prices are expected to remain stable or decline slightly due to payer negotiations.
- Use of patient assistance programs reduces net price.
- Introduction of biosimilar biologics is unlikely within the next 5 years due to manufacturing complexities.
Key Takeaways
- NDC 00703-7123 (Tafasitamab) addresses a niche but growing segment of refractory DLBCL.
- Current annual revenue potential ranges from $50 million to $100 million in the short term.
- Pricing remains high but faces downward pressure amid increasing competition and payer scrutiny.
- Growth hinges on label expansion, clinical trial success, and adoption into earlier treatment lines.
FAQs
Q1: How does Tafasitamab compare in efficacy to CAR-T therapies?
It offers a less invasive option with a different safety profile but generally lower remission rates than CAR-T.
Q2: Are there any developments indicating upcoming price changes?
No major announced adjustments; prices are likely to stay stable with incremental declines due to payer negotiations.
Q3: What is the primary driver for growth in this market?
Expansion of indications and increased clinician familiarity with non-CAR-T options.
Q4: How does reimbursement influence market penetration?
High reimbursement rates facilitate access; discounts and patient assistance programs influence net revenue.
Q5: What are the key barriers to market expansion?
Competition from CAR-T therapies and delays in regulatory or clinical development.
References
- United States Food and Drug Administration (2020). Monjuvi (Tafasitamab-cxix) for injection, for intravenous use. FDA.
- IQVIA (2022). US Oncology Market Analysis.
- Centers for Disease Control and Prevention (2021). Cancer statistics, DLBCL overview.
- EvaluatePharma (2022). Oncology drug pipeline and pricing report.
- CMS.gov (2022). Medicare reimbursement rates for biologic therapies.
